Gergely Tóth is the CEO and founder of Cantabio Pharmaceuticals. Dr. Tóth is also affiliated with the School of Pharmacy at University College London as a Honorary Lecturer and with the Research Center for Natural Sciences (Hungary) as the Head of the Research Group for Neurodegenerative Disease Drug Discovery. He is a scientist and a business professional with a long-term focus on developing therapeutics for neurodegenerative diseases. Dr. Tóth previously held various research roles in small and global biopharmaceutical companies in the U.S., where he pursued drug discovery research for Parkinson’s and Alzheimer’s diseases.
Dr. Tóth received his doctorate from the Department of Biomedical Sciences at Creighton University. He is also a graduate of the executive MBA program at the Judge Business School, University of Cambridge. He was a postdoctoral fellow at the Department of Molecular Biology at the University of California at Berkeley in 2001.